SLC9A9 and myeloid sarcoma: A GWAS performed to compare responders vs. non-responders to interferon beta (IFNβ) treatment found significant association of an intronic NHE9 variant (rs9828519) with non-response to IFNβ therapy in MS patients (Esposito et al., 2013).